spacer
home > advertise
ADVERTISING OPPORTUNITIES
Why Advertise with Samedan?

 

Samedan's range of specialist titles spans the full spectrum of pharmaceutical development, from innovation to patient, and is designed to meet the broad needs of an industry built on high-quality information, communication and expertise.

With a history going back more than a decade, Samedan's clients range from long-established industry leaders to the most recent start-ups and university spin-outs. Many clients have advertised across our entire range for years, and have come to appreciate a strong and cooperative relationship with us.

Samedan is committed to providing the perfect editorial platform for your advert. That is why our featured articles take an opinion-led, non-promotional view of the industry. This ensures that every advert enjoys maximum impact with each title's readership of 10,000+ key decision makers.

For further information about each of our titles, follow the links below. Each of our advertising executives can be contacted at the email addresses below and will be pleased to discuss how Samedan can meet your needs.

Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

European Pharmaceutical Contractor
Nicholas Matthews: nick@samedanltd.com

European BioPharmaceutical Review
David Hirsh: david@samedanltd.com

International Clinical Trials
Gessica Santoro: gessica@samedanltd.com

Pharmaceutical Manufacturing and Packing Sourcer
Nicholas Matthews: nick@samedanltd.com

Innovations in Pharmaceutical Technology
David Hirsh: david@samedanltd.com



spacer

Industry Events

PHARM Connect Congress 2018

13-14 March 2018, Corinthia Hotel Budapest, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialization in Central and Eastern Europe and the CIS region. The two days event offers the perfect setting for solution providers to present their products and services directly to key decision makers playing a key role in the pharmaceutical industry in Central Eastern Europe.
More info >>

News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement